Sfoglia per AUTORE
MARCHETTI P
Collezione AOU San Luigi di Orbassano

  

Items : 9

Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2023 Jul;187:174-184. doi: 10.1016/j.ejca.2023.03.027. Epub 2023 Mar 30.

2023
AOU San Luigi di Orbassano

Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C;

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. in Journal of hematology & oncology / J Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.

2022
ASL Torino 4
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Pinato DJ; Russo A; Russano M; Porzio G; Tiseo M; Ficorella C; Addeo A; Banna GL; Friedlaender A; Metro G; Spinelli GP; Passiglia F; Migliorino MR; Ricciardi S; Pecci F; Zoratto F; De Tursi M; Di Marino P; Mansueto G; Tuzi A; Gori S; Della Gravara L; Rastelli F; Chiari R; Macerelli M; Marchetti P; Gelibter A; Antonuzzo L; Berardi R; et alii...

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. in Journal for immunotherapy of cancer / J Immunother Cancer. 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421.

2021
AOU San Luigi di Orbassano
ASL Città di Torino
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Bordi P; Tuzi A; Cantini L; Russano M; Citarella F; Santini D; Filetti M; Zoratto F; Mansueto G; Di Marino P; Grassadonia A; Michele T; Inno A; Della Gravara L; Rocco D; Chiari R; Rastelli F; Macerelli M; Marchetti P; Siringo M; et alii...

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.

2020
AOU San Luigi di Orbassano

Belderbos RA; De Filippis M; Dal Bello MG; Della Gravara L; Bertolini F; Baldessari C; Guaitoli G; Landi L; Antonuzzo L; Scodes S; Pettoruti L; Leonetti A; D'Argento E; Ferrara MG; Nigro O; Sforza V; Follador A; Torniai M; Cantini L; Russano M; Citarella F; Occhipinti MA; Sala L; Pizzutilo P; Catino A; Filetti M; Ghidini M; Tudini M; Santoni M; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May

2020
AOU San Luigi di Orbassano

Dal Bello MG; Della Gravara L; Baldessari C; Guaitoli G; Landi L; Scodes S; Antonuzzo L; Bordi P; Buti S; D'Argento E; Ferrara MG; Sforza V; Nigro O; Targato G; Cantini L; Torniai M; Marco R; Citarella F; Sala L; Pizzutilo P; Catino A; Filetti M; Rijavec E; Tudini M; Santoni M; Zoratto F; Mansueto G; De Tursi M; Gori S; et alii...

CORE-URO-01 study: Comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure in Annals of Oncology

2017
AO Ordine Mauriziano
ASL Cuneo 2
AOU San Luigi di Orbassano

Masini C; Vitale MG; Maruzzo M; Procopio G; De Giorgi U; Buti S; Rossetti S; Iacovelli R; Guida A; Atzori F; Mucciarini C; Cosmai L; Vignani F; Prati G; Scagliarini S; Berselli A; Pinto C; Baldari S; Annibale V; Lastoria S; Tucci M; Borsatti E; Monari F; Paganelli G; Verri E; Muto P; Panareo S; Mosca A; Storto G; et alii...

Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC). in Journal of Clinical Oncology

2013
AOU San Luigi di Orbassano

Gauler TC; Besse B; Novello S; Smit EF; Plummer ER; Delord J-P; Nicodemo M; Santoro A; Barone C; Marchetti P; Conte PF; De Jonge MJ; Awada A; Mariani M; Jannuzzo MG; Petroccione A; Ceruti R; Davite C; Eberhardt WEE;

Updated safety result of a large Italian early access program (EAP) with cabazitaxel plus prednisone (CbzP) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed during or after docetaxel (D) therapy in Journal of Clinical Oncology

2012
AOU San Luigi di Orbassano

Bracarda S; Di Lorenzo G; Gasparro D; Marchetti P; Boccardo F; Martoni A; Carteni G; Fornarini G; Baldazzi V; Dogliotti L; Messina C; Sisani M;

Preliminary safety results of an Italian early-access program (EAP) with cabazitaxel plus prednisone (CbzP) in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC) in Journal of Clinical Oncology

2012
AOU San Luigi di Orbassano

Bracarda S; Di Lorenzo G; Gasparro D; Marchetti P; Boccardo F; Martoni A; Carteni G; Fornarini G; Baldazzi V; Dogliotti L; Messina C; Sisani M;